SCHEDULE: NEA Adjusts Monte Rosa Therapeutics Stake

New Enterprise Associates 17, L.P. and affiliated entities have filed an amendment to their Schedule 13D, reporting a beneficial ownership of 7.9% of Monte Rosa Therapeutics, Inc. common stock.

Summary

• This filing is an amendment (Amendment No. 4) to a Schedule 13D, originally filed on July 12, 2021, concerning the common stock of Monte Rosa Therapeutics, Inc.
• The reporting persons include New Enterprise Associates 17, L.P. (NEA 17), NEA Partners 17, L.P., NEA 17 GP, LLC, and individuals Anthony A. Florence, Jr., Mohamad H. Makhzoumi, Scott D. Sandell, Ali Behbahani, Forest Baskett, Carmen Chang, Edward T. Mathers, Paul Walker, and Rick Yang.
• As of July 6, 2026, NEA 17 beneficially owns 6,692,298 shares of Monte Rosa Therapeutics, Inc. common stock, representing 7.9% of the class.
• Ali Behbahani holds options to purchase 135,432 shares, representing an additional 0.2% of the class.
• On July 1, 2026, NEA 17 distributed 1,000,000 shares to its partners. NEA Partners 17 subsequently distributed 15,000 shares, with 11,830 shares going to an entity where Florence, Makhzoumi, and Sandell may have beneficial ownership.
• On July 2, 2026, these 11,830 shares were sold in open market transactions.
• As of April 1, 2026, Forest Baskett, Ali Behbahani, Carmen Chang, Edward T. Mathers, Paul Walker, and Rick Yang no longer beneficially own 5% or more of the Issuer's common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding ownership adjustments and reporting coordination, rather than a significant strategic or financial event.

Positives

• The filing indicates a coordinated approach to reporting ownership through a joint Schedule 13D agreement.
• Ali Behbahani holds options, suggesting potential future investment or stake increase.
• The reporting persons have established a clear process for managing and reporting their holdings, including distributions and sales.

Negatives

• The sale of 11,830 shares by an entity associated with Florence, Makhzoumi, and Sandell on July 2, 2026, indicates a reduction in their indirect holdings.
• Several individuals (Baskett, Behbahani, Chang, Mathers, Walker, Yang) have ceased to beneficially own 5% or more of the Issuer's common stock, suggesting a reduced influence or divestment.

Risks

• Depending on market conditions and other factors, NEA 17 and the Reporting Persons may dispose of additional shares of the Issuer.
• The filing does not detail the specific reasons for the distributions or sales, which could imply strategic shifts or capital allocation decisions.

Future Outlook

Depending on market conditions and other factors, NEA 17 and the Reporting Persons may dispose of additional shares of the Issuer.

Industry Context

StockSavvy.ai notes that this Schedule 13D amendment reflects ongoing portfolio management activities by venture capital firms like New Enterprise Associates. Such filings are common as firms adjust their stakes in portfolio companies, especially in the biotechnology sector where Monte Rosa Therapeutics operates, due to funding rounds, market performance, or strategic realignments.

Corporate Governance

Related Party Transactions

• NEA 17 made a pro rata distribution of 1,000,000 shares to its general partner and limited partners.
• NEA Partners 17 distributed 15,000 shares, of which 11,830 shares were received by an entity for which Florence, Makhzoumi, and Sandell may be deemed to have beneficial ownership.
• These 11,830 shares were subsequently sold in open market transactions on July 2, 2026.

Stakeholder Impact

• Shareholders: The potential for further share disposals by NEA 17 could influence stock price and liquidity.
• Investors in NEA funds: The distributions and sales reflect portfolio management decisions by NEA.
• Management of Monte Rosa Therapeutics: Awareness of significant shareholder positions and potential changes is crucial for strategic planning.

Next Steps

• NEA 17 and the Reporting Persons may dispose of additional shares of the Issuer depending on market conditions and other factors.

Key Dates

Recommendation

This filing is primarily an administrative update regarding ownership adjustments by a venture capital firm. While the potential for future share disposals exists, there is no new material information about Monte Rosa Therapeutics' business operations, financial performance, or strategic direction that would warrant a buy or sell recommendation at this time. A 'hold' reflects the current neutral stance based on the information provided.

Keywords

Schedule 13D, Monte Rosa Therapeutics, New Enterprise Associates, NEA 17, Beneficial Ownership, Stock Holdings, SEC Filing, Amendment, Venture Capital